MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch...
Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.